Intermediate Risk Non-Muscle Invasive Bladder Cancer
Oncology
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| zusduri | UroGen Pharma Ltd. (URGN) |
Phase 3(1)
| Drug | Company |
|---|---|
| Nadofaragene Firadenovec | Valneva SE (VALN) |
Compare drugs
Frequently asked questions
How many drugs are in development for Intermediate Risk Non-Muscle Invasive Bladder Cancer?
BioSniper tracks 2 drugs in development for Intermediate Risk Non-Muscle Invasive Bladder Cancer across 2 companies.
How many clinical trials target Intermediate Risk Non-Muscle Invasive Bladder Cancer?
There are 1 clinical trial targeting Intermediate Risk Non-Muscle Invasive Bladder Cancer tracked by BioSniper.
Deep-dive into Intermediate Risk Non-Muscle Invasive Bladder Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis